ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Preventive Ovarian Surgery Recommended For Women with BRCA1 Mutations by Age 35

February 28, 2014

EORTC Places Same Number on Phase 2-3 Trials As In U.S.

December 12, 1986

White House Order Poses Difficulties For NIH Peer Review

April 2, 1993

Blayney Elected ASCO President For 2009.

March 7, 2008

NCI Expects Improved Communications to Result from Consolidation of Offices

May 12, 2000

AIDs Concepts Totaling $13 Million Approved By DCT Board; Will Be Funded By Special Appropriations

October 11, 1985